dc.contributor.author | Zhang, Xi | |
dc.contributor.author | Wan, Yunxia | |
dc.contributor.author | Chata, Roberto | |
dc.contributor.author | Brazzale, Anthony | |
dc.contributor.author | Atherton, John J | |
dc.contributor.author | Kostner, Karam | |
dc.contributor.author | Dimeski, Goce | |
dc.contributor.author | Punyadeera, Chamindie | |
dc.date.accessioned | 2022-02-08T04:47:51Z | |
dc.date.available | 2022-02-08T04:47:51Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 0021-9746 | |
dc.identifier.doi | 10.1136/jclinpath-2016-203631 | |
dc.identifier.uri | http://hdl.handle.net/10072/412132 | |
dc.description.abstract | Aim Heart failure (HF) affects millions of older individuals in both developed and low/middle-income countries. Serum galectin-3 levels have been shown to have prognostic value. However, its use as a diagnostic biomarker has not been explored. The aim was to establish a saliva galectin-3 reference range and to demonstrate the potential diagnostic utility of salivary and serum galectin-3 levels in assessing HF. Methods Blood and saliva samples were collected from age-matched healthy controls (n=51) and patients with HF (n=63). Customised immunoassays were developed to quantify salivary galectin-3 levels. The diagnostic performances of these assays were evaluated by receiver operator characteristic (ROC) curves analysis. Results The galectin-3 concentrations were significantly elevated in saliva and serum samples of patients with HF compared with controls (p<0.001 and p<0.0001, respectively). Using ROC curve analysis, both serum and salivary galectin-3 gave area under the curve (AUC)=0.86 and AUC=0.73, respectively. There was also a significant correlation (r=0.4, p<0.01) between serum and salivary galectin-3 levels. Conclusions For the first time, we have quantified galectin-3 levels in human saliva and have demonstrated potential clinical utility in diagnosing HF. Further, larger multicentre clinical trials are needed before salivary galectin-3 levels can be implemented in a clinical setting. | |
dc.description.peerreviewed | Yes | |
dc.language | English | |
dc.publisher | BMJ Publishing Group | |
dc.relation.ispartofpagefrom | 1100 | |
dc.relation.ispartofpageto | 1104 | |
dc.relation.ispartofissue | 12 | |
dc.relation.ispartofjournal | Journal of Clinical Pathology | |
dc.relation.ispartofvolume | 69 | |
dc.subject.fieldofresearch | Clinical sciences | |
dc.subject.fieldofresearch | Medical microbiology | |
dc.subject.fieldofresearch | Oncology and carcinogenesis | |
dc.subject.fieldofresearchcode | 3202 | |
dc.subject.fieldofresearchcode | 3207 | |
dc.subject.fieldofresearchcode | 3211 | |
dc.subject.keywords | Science & Technology | |
dc.subject.keywords | Life Sciences & Biomedicine | |
dc.subject.keywords | Pathology | |
dc.subject.keywords | HEART-FAILURE | |
dc.subject.keywords | PLASMA GALECTIN-3 | |
dc.title | A pilot study to demonstrate diagnostic potential of galectin-3 levels in saliva | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dcterms.bibliographicCitation | Zhang, X; Wan, Y; Chata, R; Brazzale, A; Atherton, JJ; Kostner, K; Dimeski, G; Punyadeera, C, A pilot study to demonstrate diagnostic potential of galectin-3 levels in saliva, Journal of Clinical Pathology, 2016, 69 (12), pp. 1100-1104 | |
dcterms.dateAccepted | 2016-04-21 | |
dc.date.updated | 2022-02-08T04:46:57Z | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Punyadeera, Chamindie | |
gro.griffith.author | Zhang, Xi | |